Article
Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
Breast cancer research and treatment - 1 Jul 2020
Umamaheswaran Gurusamy, Kadambari Dharanipragada, Muthuvel Suresh Kumar, Kalaivani Sekar, Devi Jaganathan, Damodaran Solai Elango, Pradhan Suresh Chandra, Dubashi Biswajit, Dkhar Steven Aibor, Adithan Chandrasekaran
Abstract excerpt
PURPOSE: Musculoskeletal adverse events (MS-AEs) and vasomotor symptoms (VMSs) are the major side-effects of newer generation non-steroidal aromatase inhibitor (AI), letrozole. Single-nucleotide polymorphisms (SNPs) in CYP19A1 gene coding for the enzyme aromatase are related to AI treatment-associated adverse drug reactions. Therefore, we aimed to determine whether SNPs in the CYP19A1 gene are associated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.